Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
Survival for venetoclax and decitabine for acute myeloid leukemia
Acute myeloid leukemia

New Protocol: Venetoclax with Decitabine for AML Induction in Fit Patients

Ulas D. Bayraktar, MD
2025-06-02
Acute myeloid leukemia

New Drug: Enasidenib in IDH2 Mutant AML

Ulas D. Bayraktar, MD
2023-01-10
Acute myeloid leukemia

New Drug: Enasidenib for IDH2 Mutant AML

Ulas D. Bayraktar, MD
2022-09-20
Acute myeloid leukemia

New Protocol: Venetoclax with 3 + 7 Chemotherapy for AML

Ulas D. Bayraktar, MD
2022-07-16
Acute myeloid leukemia

New Protocol: Ivosidenib and Azacitidine in IDH1-Mutated AML

Ulas D. Bayraktar, MD
2022-05-20
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj